| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7390032 | Value in Health Regional Issues | 2016 | 9 Pages |
Abstract
Even though the simulations for Prevenar-13 and Synflorix® revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix® had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix® produced equivalent health outcomes, the overall analysis predicted that Synflorix® would save 360 million Mexican pesos, as compared with Prevenar-13.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jorge A. PhD, MCE, Alberto MD, Gerardo MartÃnez MD, Roberto Carreño MD, MarÃa Y. MD,